Given the frequent hyperactivation or deregulation of Akt/mTOR pathway in HCC [15,16,17], several small molecule inhibitors targeting this pathway have been developed and are currently undergoing preclinical or clinical trials [8,18]. This evidence concerns the gene MTOR and hepatocellular carcinoma.